Andere talen Denali Therapeutics Inc.

Aandelen

DNLI

US24823R1059

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
14,96 ^USD	-3,86%		-9,88%	-30,29%

09/04	DENALI THERAPEUTICS INC. : UBS geeft koopadvies	ZM
03/04	Denali Therapeutics Insider verkocht aandelen ter waarde van $1.896.250, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04
Denali Therapeutics Files Prospectus for Secondary Offering	22/03
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	01/03
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27/02
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27/02
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	27/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	20/02
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	16/02
Sanofi : échec d'un essai de phase 2 contre la SLA	16/02
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	16/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	07/02
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Denali Therapeutics Inc.

Aandelen

DNLI

US24823R1059

Andere talen

Filters